Loading
Life sciences · Journal article
Biomedicines · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Intravesical Bacillus Calmette–Guérin (BCG) remains the standard adjuvant treatment for intermediate- and high-risk non-muscle-invasive bladder cancer. However, 30–50% of patients fail to respond or experience recurrence within two years, while clinical and pathological risk models have limited accuracy in predicting individual response. This narrative review summarizes molecular classifications and candidate biomarkers associated with BCG response and assesses their potential clinical utility, based on a focused search of PubMed, Scopus, and Web of Science through July 2026, supplemented by ClinicalTrials.gov, regulatory documents, and current guidelines. Transcriptomic classifications, including UROMOL2021, BCG Response Subtypes (BRS), MSP888, and subtypes defined in stage T1 disease, identify tumor phenotypes associated with differences in recurrence, progression, and outcomes after BCG. BRS3 is characterized by basal-squamous and immunosuppressive features and is associated with shorter recurrence-free and progression-free survival. Genomic alterations, including FGFR3 and TERT promoter mutations and APOBEC signatures; DNA methylation markers such as GATA2, TBX3, and GPR158; and tumor microenvironment features, including regulatory T cells, exhausted CD8+ T cells, and PD-L1 expression, have been associated with outcomes in individual cohorts but remain unvalidated as treatment-specific predictors. Bladder-preserving options for BCG-unresponsive disease include pembrolizumab, nadofaragene firadenovec, nogapendekin alfa inbakicept-pmln with BCG, and the gemcitabine intravesical system. Randomized trials adding checkpoint inhibition to BCG in BCG-naive disease have reported inconsistent results. No molecular biomarker is currently validated for treatment selection. Molecular profiling remains investigational and may complement, but not replace, established clinical risk assessment. Clinical implementation requires prospective biomarker-stratified trials with standardized definitions, assays, and endpoints.